Exciting!

Systemic lupus erythematosus (SLE) is a complex chronic disea.

This year 's publication of the document " Expert Consensus on Allogeneic Mesenchymal Stem Cell Therapy for Systemic Lupus Erythematosus " means that lupus treatment has a new method for clinical referen.

Self-introduction of mesenchymal stem cells

Hello! Hello everyone, my name is mesenchymal stem cells (MSCs), which are a type of adult stem cells in the bone marrow that are different from hematopoietic stem cel.

Although I am small, my functions are very powerf.

According to the source, I can be divided into autologous mesenchymal stem cells and allogeneic mesenchymal stem cel.

Why can I be treated for SLE?

Studies have shown that compared with normal people, I in SLE patients is in an abnormal state, mainly manifested as decreased proliferation and differentiation ability, and significantly reduced secretion of immune factors such as transforming growth factor (TGF) -β, IL-6, IL-7 , e.

Systemic lupus erythematosus (SLE) is a complex chronic disea.

This year 's publication of the document " Expert Consensus on Allogeneic Mesenchymal Stem Cell Therapy for Systemic Lupus Erythematosus " means that lupus treatment has a new method for clinical referen.

Interpretation of the "Expert Consensus on Allogeneic Mesenchymal Stem Cell Therapy for Systemic Lupus Erythematosus " Stem Cell Consensus

Self-introduction of mesenchymal stem cells

Self-introduction of mesenchymal stem cells Self-introduction of mesenchymal stem cells

Hello! Hello everyone, my name is mesenchymal stem cells (MSCs), which are a type of adult stem cells in the bone marrow that are different from hematopoietic stem cel.

Placenta, fat, pulp, umbilical cord, muscle, lung, liver

Although I am small, my functions are very powerf.

Supports hematopoiesis, immune regulation, has strong proliferation ability, has huge differentiation potential, and has low immunogenic immunity

According to the source, I can be divided into autologous mesenchymal stem cells and allogeneic mesenchymal stem cel.

Why can I be treated for SLE?

Why can I be treated for SLE? Why can I be treated for SLE?

Studies have shown that compared with normal people, I in SLE patients is in an abnormal state, mainly manifested as decreased proliferation and differentiation ability, and significantly reduced secretion of immune factors such as transforming growth factor (TGF) -β, IL-6, IL-7 , e.

(TGF) -β, IL-6, IL-7 T and B cell proliferation, plasma cell differentiation

 

Everyone must know that the pathogenesis of SLE involves the overactivity of T cells and B cells, which can lead to autoimmune diseas.

Regulation suppresses T and B cell hyperactivity,

How effective and safe is my treatment for SLE?

How effective and safe is my treatment for SLE? How effective and safe is my treatment for SLE?

As of July 2021, among the literatures about my treatment of SLE included in CNKI, most of them received allogeneic MSC therapy (691 cases), and only a few received autologous MSC therapy (4 case.

Allogeneic MSC therapy Autologous MSC therapy

• Efficacy: 65% of SLE patients achieved complete remission or partial remission after 1 year of allogeneic MSC treatment , and laboratory indicators such as 24h urine protein decreased significantly; 50% of patients still achieved clinical remission after 4 years of treatment, and the 4-year survival rate was 94% , the overall recurrence rate was 23% ;

Efficacy: 65% of SLE patients achieved complete remission or partial remission after 1 year of allogeneic MSC treatment , and laboratory indicators such as 24h urine protein decreased significantly; 50% of patients still achieved clinical remission after 4 years of treatment, and the 4-year survival rate was 94% , the overall recurrence rate was 23% ;

Efficacy: 65% of SLE patients achieved complete remission or partial remission after 1 year of allogeneic MSC treatment , and laboratory indicators such as 24h urine protein decreased significantly; 50% of patients still achieved clinical remission after 4 years of treatment, and the 4-year survival rate was 94% , the overall recurrence rate was 23% ;

After 1 year 65% After 4 years of treatment, 50% 94% 23%

• Safety: Most of the patients tolerated my treatment well, and a small number of patients had reactions such as fever, sweating, palpitations, and facial flushin.

  
  

Safety: Most of the patients tolerated my treatment well, and a small number of patients had reactions such as fever, sweating, palpitations, and facial flushin.

Safety: Most of the patients tolerated my treatment well, and a small number of patients had reactions such as fever, sweating, palpitations, and facial flushin.

There were no serious adverse reactions and no transplant-related dea.

In a safety analysis of 404 patients with SLE, with a mean follow-up time of (43±26) months, no increase in infection and tumor events was fou.

Fever, sweating, palpitations, facial flushing infection

To sum up, it can be seen that my treatment of SLE has good efficacy, high safety, and can reduce the risk of infecti.

It is safer and reduces the risk of infecti.

Who am I suitable for SLE patients?

Who am I suitable for SLE patients? Who am I suitable for SLE patients?

Although I have good efficacy and high safety, it does not mean that I am suitable for all SLE patien.

My suitable patients are: moderate to severe SLE, especially active SLE patients with kidney, blood, lung, skin and other organ involveme.

Source: Literature

Moreover, before SLE patients use me for treatment, the attending doctor needs to formulate an appropriate MSC plan according to the patient's disease activity, organ involvement and individual differences ! How should it be used to treat SLE?

How should disease activity, organ involvement and individual differences be used to treat SLE?

Peripheral intravenous infusion is generally recommend.

For patients with severe SLE involving the central nervous system, it is recommended to inject 1x 10 ⁶ MSC intrathecally at the same time as peripheral intravenous infusion of M.

Intrathecal injection is not recommended for unconscious patien.

10 ^{6 6}

What precautions should I take when using me?

What precautions should I take when using me? What precautions should I take when using me?

• It is recommended to take aspirin or clopidogrel hydrogen sulfate (75-100mg/d) one day before allogeneic infusion for two consecutive weeks (except for long-term prophylaxis users, those with bleeding tendency should be used with caution) to prevent thrombosis events;

• There is no need to stop hormones and immunosuppressants after the infusion, and the dose can be adjusted in time according to the patient's condition, but it is not recommended to use cyclophosphamide within 48 hours after the infusion;

• After 6 months of treatment remission, some patients may relapse, and relapsed patients can be treated with repeated MSC infusion;

It is recommended to take aspirin or clopidogrel hydrogen sulfate (75-100mg/d) one day before allogeneic infusion for two consecutive weeks (except for long-term prophylaxis users, those with bleeding tendency should be used with caution) to prevent thrombosis events;

It is recommended to take aspirin or clopidogrel hydrogen sulfate (75-100mg/d) one day before allogeneic infusion for two consecutive weeks (except for long-term prophylaxis users, those with bleeding tendency should be used with caution) to prevent thrombosis events;

Aspirin or clopidogrel bisulfate (75-100mg/d) to prevent thrombosis

There is no need to stop hormones and immunosuppressants after the infusion, and the dose can be adjusted in time according to the patient's condition, but it is not recommended to use cyclophosphamide within 48 hours after the infusion;

There is no need to stop hormones and immunosuppressants after the infusion, and the dose can be adjusted in time according to the patient's condition, but it is not recommended to use cyclophosphamide within 48 hours after the infusion;

Cyclophosphamide is not recommended within 48 hours after infusion;

After 6 months of treatment remission, some patients may relapse, and relapsed patients can be treated with repeated MSC infusion;

After 6 months of treatment remission, some patients may relapse, and relapsed patients can be treated with repeated MSC infusion;

• It is not recommended for patients with severe pulmonary hypertension [>70mmHg (1mmHg=133kpa)];

• It is not recommended for breastfeeding and pregnant patients for the time being ;

• After infusion, it is necessary to regularly monitor the function indicators of affected organs, serum immunological indicators (including autoantibody titers, complement levels, Treg cells), e.
  
  ;

• Patients with blood system and renal system involvement should regularly review blood routine, liver function, renal function, 24-hour urine protein quantification, organ B-ultrasound, e.
  
  

It is not recommended for patients with severe pulmonary hypertension [>70mmHg (1mmHg=133kpa)];

It is not recommended for patients with severe pulmonary hypertension [>70mmHg (1mmHg=133kpa)];

It is not recommended for breastfeeding and pregnant patients for the time being ;

It is not recommended for breastfeeding and pregnant patients for the time being ;

Not recommended for breastfeeding and pregnant patients

After infusion, it is necessary to regularly monitor the function indicators of affected organs, serum immunological indicators (including autoantibody titers, complement levels, Treg cells), e.

;

After infusion, it is necessary to regularly monitor the function indicators of affected organs, serum immunological indicators (including autoantibody titers, complement levels, Treg cells), e.

;

Patients with blood system and renal system involvement should regularly review blood routine, liver function, renal function, 24-hour urine protein quantification, organ B-ultrasound, e.

Patients with blood system and renal system involvement should regularly review blood routine, liver function, renal function, 24-hour urine protein quantification, organ B-ultrasound, e.

Regular review

write at the end

write at the end write at the end

At present, the technology of MSC treatment of SLE is not yet fully mature and needs to be developed, but the publication of the expert consensus means that MSC treatment of SLE has achieved a good stage result

The editor and everyone look forward to the early development of MSCs into new drugs for the treatment of SLE and contribute to the health of SLE patien.

better stage results

Reminder: This article is based on the sharing of disease science and cannot replace hospital visi.

Opinions are for reference only, please follow the doctor's advice for specific treatment metho.

references:

[1] Rheumatology Branch of Chinese Medical Association, Professional Committee of Clinical Technology Application of Chinese Hospital Associati.

Expert consensus on the treatment of systemic lupus erythematosus with allogeneic mesenchymal stem cells [.

Chinese Journal of Rheumatology, 2022, 26(1):

leave a message here